ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

BACKGROUND: ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an immunostimulatory state. Combining ONCOS-102 with standard-of-care chemotherapy for malignant pleural mesothelioma (MPM) may improve treatment outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponce, Santiago, Cedrés, Susana, Ricordel, Charles, Isambert, Nicolas, Viteri, Santiago, Herrera-Juarez, Mercedes, Martinez-Marti, Alex, Navarro, Alejandro, Lederlin, Mathieu, Serres, Xavier, Zugazagoitia, Jon, Vetrhus, Sylvia, Jaderberg, Magnus, Hansen, Thomas Birkballe, Levitsky, Victor, Paz-Ares, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476122/
https://www.ncbi.nlm.nih.gov/pubmed/37661097
http://dx.doi.org/10.1136/jitc-2023-007552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476122/
https://www.ncbi.nlm.nih.gov/pubmed/37661097
http://dx.doi.org/10.1136/jitc-2023-007552

Ejemplares similares